FDA Drug Safety Process Subject To IoM Review Under Agency Initiative
This article was originally published in The Tan Sheet
Executive Summary
FDA will sponsor an Institute of Medicine study of the agency's drug safety process as part of a broad initiative to strengthen the pre- and post-market evaluation of drugs
You may also be interested in...
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report